)
Visual
test
Ovid Therapeutics
Ovid Therapeutics (OVID) investor relations material
Ovid Therapeutics Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary15 Dec, 2025
Company overview and business model
Focuses on developing small molecule medicines for brain conditions with significant unmet need, particularly epilepsies and neurological disorders.
Pipeline includes three novel mechanisms of action targeting seizures, with two programs in clinical trials and a third expected to enter trials in Q2 2026.
Initial indications include epilepsy and psychoses associated with Parkinson's disease and Lewy body dementia, with plans to expand to broader neurologic indications.
Founded in 2014 and headquartered in New York, with common stock listed on Nasdaq under the symbol "OVID."
Financial performance and metrics
As of December 15, 2025, 130,184,353 shares of common stock outstanding.
Last reported sale price of common stock was $1.64 per share on December 12, 2025.
Use of proceeds and capital allocation
Will not receive any proceeds from the sale of shares by selling stockholders; all proceeds go to selling stockholders.
Company will bear registration costs, while selling stockholders bear underwriting fees, commissions, and transfer taxes.
OV4071 IND/CTA clearance timeline
Future funding strategy post-private placement
Impact of beneficial ownership limits on large holders?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebGEVO
Scaling low-carbon fuel production and software, targeting major growth and plant expansion. - 5 FebARES
AUM climbed 29% to $622.5B, with record fundraising, earnings, and a 20% dividend increase. - 5 FebFR
FFO per share rose 11.7% in 2025, with strong leasing and a 12.4% dividend increase. - 5 FebBTU
Centurion Mine launch and strong cash flow position drive higher 2026 met coal volumes and returns. - 5 Feb033780
Record earnings, robust shareholder returns, and global expansion mark 2025; moderate growth targeted for 2026. - 5 FebWST
Integrated PFS system accelerates development, reduces risk, and simplifies compliance. - 5 FebCMS
2025 adjusted EPS up 8%+ to $3.61, 2026 guidance raised, $24B plan drives growth. - 5 FebCHILE
2025 net income reached CLP 1,192,262 million, with strong capital and digital-driven growth ahead. - 5 FebORLY
Record 2025 results with 6% sales and 10% EPS growth, plus strong 2026 outlook. - 5 FebOWL
AUM surpassed $300 billion in 2025 amid record fundraising and double-digit earnings growth.
Next Ovid Therapeutics earnings date
Q4 202511 Mar, 2026
Ovid Therapeutics
Next Ovid Therapeutics earnings date
Q4 202511 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for rare neurological disorders. The company specializes in small-molecule and genetic-based therapies targeting conditions such as epilepsies and neurodevelopmental syndromes. Its research and development efforts aim to advance novel drug candidates through clinical trials and regulatory approvals. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage